| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | SR-II-138A | CTRPv2 | pan-cancer | AAC | 0.099 | 0.002 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.002 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.003 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.003 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.003 |